

Amendments to the Abstract:

Please replace the abstract with the following rewritten abstract

The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-*N*-({(5*S*)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, the pharmaceutical composition resulting from this process, and its use for the prophylaxis and/or treatment of thromboembolic diseases.